Initially, we utilized bioinformatics analysis and CRISPR/Cas9 technology to establish PIK3CA mutant and wild-type NSCLC cell lines, identifying the key pathways and genes targeted by TSRP therapy. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.